Protalix BioTherapeutics Inc. (PLX) Quarterly 10-Q Report

4 days ago · Protalix BioTherapeutics, Inc. has submitted its 10-Q filing for the quarterly period ended September 30, 2024. Revenues from license and R&D services decreased to $0.1 …

CouponFollow Extension

$0
OFF

Protalix BioTherapeutics Inc. (PLX) Quarterly 10-Q Report

1 week from now

4 days ago · Protalix BioTherapeutics, Inc. has submitted its 10-Q filing for the quarterly period ended September 30, 2024. Revenues from license and R&D services decreased to $0.1 …

qz.com

$0
OFF

Protalix BioTherapeutics Inc (PLX) Quarterly 10-Q Report

1 week from now

4 days ago · Protalix BioTherapeutics, Inc. has submitted its 10-Q filing for the quarterly period ended September 30, 2024. Revenues from license and R&D services decreased to $0.1 …

qz.com

FAQs about Protalix BioTherapeutics Inc. (PLX) Quarterly 10-Q Report Coupon?

Is Protalix Biotherapeutics a recombinant biopharmaceutical company?

Protalix BioTherapeutics, Inc. (NYSE: PLX), a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins, recently disclosed its financial outcomes for the fiscal quarter concluding on September 30, 2024. ...

Did Protalix BioTherapeutics (PLX) release Q3 earnings?

Protalix Biotherapeutics ( (PLX) ) has released its Q3 earnings. Here is a breakdown of the information Protalix Biotherapeutics presented to its investors. ...

When is Protalix BioTherapeutics' third-quarter conference call?

Investors and stakeholders keen on delving deeper into Protalix BioTherapeutics’ third-quarter achievements and future prospects can access additional details through the company’s online platforms and are encouraged to participate in the conference call scheduled for November 14, 2024, at 8:30 a.m. EST. ...

Does Protalix BioTherapeutics have a gout treatment?

In its third-quarter 2024 financial report, Protalix BioTherapeutics announced significant progress in its clinical trials and financial metrics. The company completed its phase I study of PRX-115 for treating uncontrolled gout, showing promising preliminary results that highlight the treatment’s potential efficacy and safety. ...

Does Protalix repay its debt?

The reports were followed by a conference call which discussed recent achievements, clinical updates and financial performance. Since the second quarter update, Protalix has repaid its convertible debt and completed the eighth cohort of its Phase I PRX-115 trial in gout. ...

Is Protalix preparing for a Phase II clinical trial?

Strategically, Protalix is poised to initiate a phase II clinical trial for PRX-115 by the second half of 2025, which could further solidify its pipeline and market position. Additionally, the company’s reduced research and development expenses, along with lower administrative costs, have contributed to its improved financial health. ...